Pharmacological treatment of memory disorders caused by hypoxia and cerebral ischemia in rats
Animal research · 1998
- What was studied
- Rat hypoxia / cerebral-ischemia memory models
- Main finding
- The indexed abstract identifies GVS-111 among nootropics investigated in hypoxia/ischemia-associated memory impairment.
Study data at a glance
- Participants or experimental model
- Rat hypoxia / cerebral-ischemia memory models
- Reported results
- The indexed abstract identifies GVS-111 among nootropics investigated in hypoxia/ischemia-associated memory impairment.
Study limitations and source details
Study limitations
- Original results and compound-specific effects require full-paper extraction.
- Not a human occupational trial.
Source details
Indexed primary abstract identified; full author list and methods remain pending.
Sources checked
Citation
Author transcription pending. Pharmacological treatment of memory disorders caused by hypoxia and cerebral ischemia in rats Aviakosm Ekolog Med. 32(1):55–60
Related compounds
Noopept
Omberacetam (GVS-111), a synthetic derivative of the Pro–Gly dipeptide. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester. Studies examined cognition and the metabolite cycloprolylglycine.
Semax
A synthetic heptapeptide, Met–Glu–His–Phe–Pro–Gly–Pro (MEHFPGP). It combines residues 4–7 of adrenocorticotropic hormone (ACTH) with Pro–Gly–Pro and has been studied in ischemic stroke.